Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Griffin William L. Jr
   2. Issuer Name and Ticker or Trading Symbol
Wright Medical Group N.V. [WMGI] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
SVP GM BioMimetic Therapeutics
(Last)
(First)
(Middle)
1023 CHERRY ROAD		 3. Date of Earliest Transaction (Month/Day/Year)
10/01/2015
(Street)

MEMPHIS, TN 38117		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares, par value EUR 0.03 per share 10/01/2015   A   71,126 A (1) 71,126 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $ 28.99 10/01/2015   A   103,090   10/01/2015 07/22/2018 Ordinary Shares 103,090 (2) 103,090 D  
Stock Option (Right to Buy) $ 15.01 10/01/2015   A   12,175   10/01/2015 05/13/2019 Ordinary Shares 12,175 (3) 12,175 D  
Stock Option (Right to Buy) $ 17.82 10/01/2015   A   10,191   10/01/2015 05/13/2020 Ordinary Shares 10,191 (4) 10,191 D  
Stock Option (Right to Buy) $ 15.04 10/01/2015   A   13,252   10/01/2015 05/11/2021 Ordinary Shares 13,252 (5) 13,252 D  
Stock Option (Right to Buy) $ 17.7 10/01/2015   A   2,036   10/01/2015 04/16/2022 Ordinary Shares 2,036 (6) 2,036 D  
Stock Option (Right to Buy) $ 20.75 10/01/2015   A   20,687   10/01/2015 05/09/2022 Ordinary Shares 20,687 (7) 20,687 D  
Stock Option (Right to Buy) $ 23.93 10/01/2015   A   20,564   10/01/2015 05/14/2023 Ordinary Shares 20,564 (8) 20,564 D  
Stock Option (Right to Buy) $ 29.06 10/01/2015   A   18,137   10/01/2015 05/13/2024 Ordinary Shares 18,137 (9) 18,137 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Griffin William L. Jr
1023 CHERRY ROAD
MEMPHIS, TN 38117		       SVP GM BioMimetic Therapeutics  

Signatures

 /s/ Marija S. Nelson, Attorney-in-fact   10/05/2015
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Received in exchange for 68,995 common shares of Wright Medical Group, Inc. ("Wright") pursuant to the Agreement and Plan of Merger by and among the issuer, Tornier N.V. ("TRNX"), Trooper Holdings Inc., and Trooper Merger Sub Inc., which became effective on October 1, 2015, (the "Merger"). On the date prior to the effective time of the Merger, the closing price of Wright's common shares was $21.02 per share and the closing price of TRNX's ordinary shares was $20.39 per share.
(2) Received in the merger in exchange for an employee stock option to acquire 100,000 Wright shares for $29.88 per share.
(3) Received in the merger in exchange for an employee stock option to acquire 11,811 Wright shares for $15.47 per share.
(4) Received in the merger in exchange for an employee stock option to acquire 9,886 Wright shares for $18.37 per share.
(5) Received in the merger in exchange for an employee stock option to acquire 12,855 Wright shares for $15.50 per share.
(6) Received in the merger in exchange for an employee stock option to acquire 1,975 Wright shares for $18.24 per share.
(7) Received in the merger in exchange for an employee stock option to acquire 20,067 Wright shares for $21.39 per share.
(8) Received in the merger in exchange for an employee stock option to acquire 19,948 Wright shares for $24.66 per share.
(9) Received in the merger in exchange for an employee stock option to acquire 17,594 Wright shares for $29.95 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.